Search
Zentalis Pharmaceuticals Inc
ZNTLAdd to Watchlist
2.750USD
-0.120-4.18%
Close 09-24 16:00（ET）
195.77MMarket Cap
LossP/E TTM
Zentalis Pharmaceuticals Inc (ZNTL) Stock Price Target & Forecast
Analyst Rating
Based on 10 analysts giving stock ratings to Zentalis Pharmaceuticals Inc in the past month.
Buy
2 Strong Buy
3 Buy
5 Hold
0 Sell
0 Strong Sell
Target Price
6.889USD+140.03%
ZNTL Analyst Recommendation Trends
In the current month, ZNTL has received 3 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. ZNTL average Analyst price target in the last month is 6.889.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
2
2
2
2
2
2
2
2
3
3
2
2
2
2
2
2
5
5
5
5
5
5
5
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
10
9
9
9
9
9
9
ZNTL Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
13
5
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, ZNTL EPS is projected to reach -0.566 in FY2026Q3, following reported EPS of -0.593 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.58
-0.48
-0.49
-0.57
-0.54
Actual
-0.49
-0.50
-0.59
--
--
Surprise
+15.13%
-5.58%
-21.02%
--
--
FAQs
What is Zentalis Pharmaceuticals Inc's price target?
Analysts forecast that Zentalis Pharmaceuticals Inc's price target is USD 6.89, with the highest forecast at USD 10.00 and the lowest forecast at USD 4.00.
How have Zentalis Pharmaceuticals IncZNTL's recent earnings per share performed?
The market expectation was USD -0.59, while Zentalis Pharmaceuticals IncZNTL's earnings per share (EPS) for the previous quarter was USD -0.50. EPS for the next quarter is expected at USD -0.57.
What is the analyst rating for Zentalis Pharmaceuticals Inc?
Based on the ratings of Zentalis Pharmaceuticals Inc's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.